|
[Objective] To study in The transplanted rat hepatic ischemia / reperfusion injury in animal models (Liver Ischemia Reperfusion) to observe the animal liver ischemia / reperfusion organizational change detection rat liver ischemia / reperfusion injury of TNF-a, ICAM-1 and NO expression, and to explore the therapeutic effect and mechanism of breviscapine extracts of rat liver graft ischemia / reperfusion. 【Method】 Kamada's cuff technique for orthotopic liver transplantation model. 105 SD rats were randomly divided into normal group, sham operation group, blank control group, the low dose Dengzhanhua injection group and high dose erigeron injection group, the rats were randomly divided into normal group (normal group, N) five SD rats were randomly selected, without any treatment, and harvested after anesthesia. Sham group (Sham operation group, SH) to open the abdominal cavity, free liver, ligation of the left every vein, right adrenal vein and hepatic artery. Blank control group (the blank controlgroup, CK) three days before a day by the right lower quadrant for by body intraperitoneal injection of saline 2ml daily, the day of surgery immediately after surgery receptor dorsal penile vein patch into 5% sodium bicarbonate and Ringer 1:5 mixture 2ml. Preoperative low dose group (low-dose treatment group, L) (5mg/kg) daily by the donor celiac 3rd to give containing 1mg Breviscapine, saline 2ml, the day of surgery, preoperative two hours with the former donor administered once by intraperitoneal surgery three days before to the receptor the saline containing 1.25mg Breviscapine 2ml, immediately after surgery receptor saline containing of 1.25mg Breviscapine the dorsal penile vein to 0.125ml time to 5 % sodium bicarbonate and Ringer mixture 2 ml of 1:5. Preoperative high dose group (high-dose treatment group, H) (7mg/kg) 3rd daily by the donor celiac to contain 1.4mg breviscapine saline 2ml, the day of surgery, preoperative two hours with the former for body administered once 2ml saline containing 1.75mg breviscapine surgery three days prior to the receptor daily once, immediately after surgery to the dorsal penile vein to receptor Containing 1.75mg Breviscapine, saline 0.175ml time and to 5% sodium bicarbonate and Ringer mixture 2 ml of 1:5. Respectively in rat liver graft open blood flow 1h after animals in each group were sacrificed. Blood samples were collected from the inferior vena cava; liver mid-right half of -70 ℃, the left half of the 10% formalin-fixed, paraffin-embedded, sliced ??underwent morphological examination. The observed liver graft reperfusion after 1h 6h and 24h liver tissue TNF-a expression of ICAM-1 and NO content in serum and liver tissue and serum ALT and AST activity and liver tissue changes of breviscapine of these indicators. The immunohistochemical results computer image analysis software (Image-Pro Plus, IPP) analysis, measurement of TNF-a, ICAM-1 integral optical density (IOD) values ??calculated TNF-a, ICAM-1 concentration. The data were statistically analyzed using SPSS15.0 Windows. [Results] The transplanted liver ischemia / reperfusion injury, serum ALT, AST levels, liver tissue TNF-a expression of ICAM-1 and NO activity was significantly higher (P <0.01), liver cell morphology abnormal changes. The pretreatment group Breviscapine, abnormal changes of these indicators were significantly reduced, difference was statistically significant (P <0.01). A normal group of rats with normal liver morphology TNF-αICAM in-1 no positive staining. 2 sham group and blank control group, TNF-a positive expression of ICAM-1 began to increase, a significant increase in 6 hours, 24 hours reduced. TNF-a, ICAM-1 expression and normal group at all time points compared, respectively, P <0.05. 3 breviscapine low high-dose group at each time point liver pathology lighter according to the blank control group, at each time point of TNF- a, ICAM-1 expression levels than those in the control group the same point in time less; pairwise comparison P value of P <0.05, and the normal group, P <0.05. [Conclusion] TNF-a expression of ICAM-1 and NO hepatic ischemia / reperfusion injury (HepaticIschemia / Reperfusion Injury, HIRI) the important risk factors breviscapine reduce TNF-a, ICAM-1, and the content of NO alleviate HIRI. The protective effect of the donor liver. The protective effects through inhibition of TNF-a, ICAM-1 secreting cells the activity of the reduction of TNF-a, achieved by the excessive secretion of the ICAM-1.
|